#generics

HIV clinics could lose over $100 million each year—notably those serving Black, brown, queer and Southern communities.

The availability of multiple, low-cost generic versions of PrEP should be good news for access. But will it be?

Several formulations of generic Truvada are now available at a lower cost.

Plus, nearly a third of people already taking Truvada for PrEP switched to the new combination pill.

An HIV prevention roundup

“All insurers failing to offer PrEP without cost sharing beginning in January 2021 are clearly not following the law.”

Globally, a child contracts HIV every 100 seconds. A new, affordable treatment is available, but the COVID-19 pandemic hinders access.

Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.

A low-cost generic version of Truvada as PrEP will hit the market September 30.

The global supply of tenofovir and six other important generic drugs must be ensured, warns a UNAIDS analysis.

Fact-checkers and HIV advocates break down the president’s State of the Union boasts.

A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.

“This is excellent news for all children living with HIV.”

Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.

Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.

At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.